Clinical trials: Eosinophils
Allergic Asthma
The Effect of Salmeterol on Eosinophil (EOS) Function
This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen…
- Trial name
- NCT00214019
- Testing
- salmeterol, Fluticasone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Asthma
Dietary Supplementation With Soy Isoflavones in Asthma
An epidemiologic study of patients with asthma has shown that increased intake of soy isoflavones correlates with less severe asthma.
- Trial name
- NCT00277446
- Testing
- Soy isoflavones
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Northwestern University
Asthma
Steroids In Eosinophil Negative Asthma
Because approximately half of all mild-moderately-severe asthma is persistently non-eosinophilic, it is important to determine prospectively if patients who are persistently non-eosinophilic differ in their benefit from inhaled…
- Trial name
- SIENA (NCT02066298)
- Testing
- Mometasone 220mcg BID, Tiotropium Respimat 5mcg QD
- Where
- 25 sites in United States
- Volunteers
- 295 people
- Sponsor
- Milton S. Hershey Medical Center
Allergic Conjunctivitis
Effect of Olopatadine on Allergic Tear Mediators
The purpose of the research is to determine which inflammatory substances are involved in causing allergic symptoms in the eye. Allergic conjunctivitis is a common problem with symptoms of temporary redness, itching, tearing, and…
- Trial name
- NCT00609128
- Testing
- olopatadine
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Asthma
Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects
The aim of the present study is to investigate whether the effects of salmeterol in combination with fluticasone propionate on blood markers of airway inflammation are maintained after chronic dosing and whether the effect is…
- Trial name
- NCT00517634
- Testing
- FP, SFC
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant…
- Trial name
- RECAP-5 (NCT05672030)
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
This study will evaluate two dose regimens of mepolizumab [75mg intravenous (i.v.) or 100mg subcutaneous (SC) every 4 weeks] compared with placebo over a 32 week treatment period in subjects with severe refractory asthma with…
- Trial name
- NCT01691521
- Testing
- Mepolizumab IV, Mepolizumab SC
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 580 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic asthma.
- Trial name
- NCT02135692
- Testing
- Mepolizumab, SOC
- Where
- 114 sites in United States, Argentina and 16 more
- Volunteers
- 339 people
- Sponsor
- GlaxoSmithKline
Eosinophils, Asthma
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and…
- Trial name
- NCT03052725
- Testing
- reslizumab
- Where
- 134 sites in United States, Belgium and 11 more
- Volunteers
- 391 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
- Trial name
- PASSAGE (NCT05329194)
- Testing
- Tezepelumab
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic…
- Trial name
- KRYPTOS (NCT04322708)
- Testing
- lirentelimab (AK002)
- Where
- 78 sites in United States, Australia and 1 more
- Volunteers
- 277 people
- Sponsor
- Allakos Inc.
Pulmonary Disease, Chronic Obstructive
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study designed to confirm the benefits of mepolizumab treatment on moderate or severe exacerbations in chronic obstructive pulmonary disease…
- Trial name
- MATINEE (NCT04133909)
- Testing
- Mepolizumab
- Where
- 339 sites in United States, Argentina and 24 more
- Volunteers
- 806 people
- Sponsor
- GlaxoSmithKline
COPD
A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab.
- Trial name
- SUMMER (NCT05138250)
- Testing
- Mepolizumab 100 MG
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Asthma
Role of Eosinophils in the Proliferation of Airway Smooth Muscle (ASM) Cells
Being a key player in Asthma, eosinophils constitute a potential target to interfere with the series of biological events leading to Asthma pathogenesis.
- Trial name
- NCT01082952
- Where
- Saudi Arabia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- King Saud University
Asthma
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab administered subcutaneously (SC) in addition to standard of care in subjects who participated in the MEA112997 study.
- Trial name
- NCT01691859
- Testing
- Mepolizumab
- Where
- 64 sites in United States, Argentina and 11 more
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory…
- Trial name
- NCT01842607
- Testing
- Mepolizumab
- Where
- 137 sites in United States, Argentina and 17 more
- Volunteers
- 651 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma, Asthma
Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count…
- Trial name
- EXHALE-1 (NCT04046939)
- Testing
- Dexpramipexole
- Where
- 36 sites in United States
- Volunteers
- 534 people
- Sponsor
- Knopp Biosciences
Asthma
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
This is a randomised, double-blind, placebo-controlled, parallel-group, multicenter study of mepolizumab in comparison with placebo in reducing Oral Corticosteroid (OCS) use in subjects with severe refractory asthma.
- Trial name
- NCT01691508
- Testing
- Mepolizumab, OCS (prednisone/prednisolone)
- Where
- 47 sites in United States, Australia and 8 more
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Asthma
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma…
- Trial name
- DREAM (NCT01000506)
- Testing
- Mepolizumab 750, Mepolizumab 250, Mepolizumab 75
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 621 people
- Sponsor
- GlaxoSmithKline